Intec Pharma (NASDAQ:NTEC) was upgraded by equities researchers at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued on Saturday.
Several other analysts have also recently commented on the stock. HC Wainwright set a $16.00 price objective on shares of Intec Pharma and gave the company a “buy” rating in a research note on Thursday, August 16th. Oppenheimer set a $15.00 price objective on shares of Intec Pharma and gave the company a “buy” rating in a research note on Wednesday, August 15th. Roth Capital initiated coverage on shares of Intec Pharma in a research note on Friday, October 5th. They set a “buy” rating and a $8.50 price objective for the company. ValuEngine upgraded shares of Intec Pharma from a “hold” rating to a “buy” rating in a research note on Friday, November 16th. Finally, Zacks Investment Research upgraded shares of Intec Pharma from a “hold” rating to a “buy” rating and set a $5.50 price objective for the company in a research note on Wednesday, October 17th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Intec Pharma has an average rating of “Buy” and a consensus price target of $12.00.
NTEC stock opened at $7.35 on Friday. The company has a market capitalization of $257.03 million, a P/E ratio of -4.45 and a beta of 0.75. Intec Pharma has a 52 week low of $3.55 and a 52 week high of $8.08.
Intec Pharma (NASDAQ:NTEC) last announced its quarterly earnings data on Friday, November 9th. The biotechnology company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.03. Analysts anticipate that Intec Pharma will post -1.33 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently made changes to their positions in the business. PNC Financial Services Group Inc. acquired a new position in shares of Intec Pharma in the 2nd quarter valued at $220,000. Renaissance Technologies LLC lifted its stake in shares of Intec Pharma by 484.3% in the 2nd quarter. Renaissance Technologies LLC now owns 88,898 shares of the biotechnology company’s stock valued at $391,000 after purchasing an additional 73,684 shares during the period. Laurion Capital Management LP acquired a new position in shares of Intec Pharma in the 3rd quarter valued at $532,000. ARK Investment Management LLC acquired a new position in shares of Intec Pharma in the 3rd quarter valued at $609,000. Finally, 683 Capital Management LLC acquired a new position in shares of Intec Pharma in the 2nd quarter valued at $660,000. Institutional investors and hedge funds own 39.67% of the company’s stock.
About Intec Pharma
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.
Further Reading: Dow Jones Industrial Average (DJIA)
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.